Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia

Autor:	Augusto Ferraris, J. C. Bandi, Marcelo M. Serra, María Laura Gonzalez, Carolina Vázquez
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Male Blood transfusion medicine.medical_treatment Anticoagulant Therapy Cardiac index 030204 cardiovascular system & hematology Liver transplantation Pathology and Laboratory Medicine Gastroenterology Biochemistry Vascular Medicine Severity of Illness Index 0302 clinical medicine Medicine and Health Sciences Medicine Multidisciplinary Pharmaceutics Liver Diseases Anemia Hematology Middle Aged Clinical Laboratory Sciences Bevacizumab Cardiovascular Therapy Treatment Outcome 030211 gastroenterology & hepatology Female Telangiectasia Hereditary Hemorrhagic medicine.drug Research Article Adult medicine.medical_specialty Gastrointestinal bleeding Science Cardiology Argentina Hemorrhage 03 medical and health sciences Signs and Symptoms Drug Therapy Diagnostic Medicine Internal medicine Humans Blood Transfusion Hemoglobin Iron Deficiency Anemia Aged Retrospective Studies Heart Failure business.industry Transfusion Medicine Anemia Refractory Hemodynamics Biology and Life Sciences Proteins medicine.disease Iron-deficiency anemia Heart failure business
Zdroj:	PLoS ONE PLoS ONE, Vol 15, Iss 2, p e0228486 (2020)
ISSN:	1932-6203
Popis:	Objective To report our clinical experience with bevacizumab in a cohort of Hereditary Hemorrhagic Telangiectasia (HHT) patients with severe hepatic involvement and/or refractory anemia. Methods Observational, ambispective study of the Institutional Registry of HHT at Hospital Italiano de Buenos Aires. Patients were treated with bevacizumab due to iron deficiency refractory anemia secondary to nasal/gastrointestinal bleeding and/or high output cardiac failure. We describe basal clinical data, bevacizumab schedules, efficacy outcomes and adverse events. Wilcoxon signed ranks test and longitudinal analysis were conducted. Results Twenty adult patients were included from July 2013 to June 2019. Clinical indications were: 13 for anemia, 4 for heart failure and 3 for both. In the anemia group, median pretreatment hemoglobin was 8.1 g/dl [IQR: 7.2–8.4] and median transfusion requirement was 4 units [2–6]. In heart failure group, pretreatment median cardiac index was 4.5 L/min/m2 [4.1–5.6] and cardiac output was 8.3 L/min [7.5–9.2]. Bevacizumab 5 mg/kg/dose every 2 weeks for 6 applications was scheduled. By the end of induction, median hemoglobin at 3 months was 10.9 g/dl [9.5–12.8] (p = 0.01) and median transfusion requirement 0 units [0–1] (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6edfab50250e31de961f0eb5e8869c http://europepmc.org/articles/PMC7006931 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.